Quest Partners LLC Has $742,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Quest Partners LLC increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 36,146.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,334 shares of the biopharmaceutical company’s stock after buying an additional 37,231 shares during the period. Quest Partners LLC’s holdings in Catalyst Pharmaceuticals were worth $742,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CPRX. Sei Investments Co. raised its position in shares of Catalyst Pharmaceuticals by 64.3% during the first quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company’s stock worth $1,329,000 after acquiring an additional 32,621 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Catalyst Pharmaceuticals during the 2nd quarter worth approximately $258,000. Integral Health Asset Management LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $4,260,000. GSA Capital Partners LLP bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $625,000. Finally, Vanguard Group Inc. boosted its position in Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after acquiring an additional 860,244 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

CPRX has been the topic of a number of research reports. Stephens began coverage on shares of Catalyst Pharmaceuticals in a research report on Monday. They set an “overweight” rating and a $35.00 target price on the stock. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Truist Financial raised their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Citigroup upped their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Trading Down 0.1 %

Shares of Catalyst Pharmaceuticals stock opened at $21.12 on Friday. The business’s fifty day simple moving average is $21.09 and its 200 day simple moving average is $18.47. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.00 and a 12 month high of $24.27. The firm has a market capitalization of $2.52 billion, a P/E ratio of 17.90, a price-to-earnings-growth ratio of 3.29 and a beta of 0.75.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.